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Abstract 
 
In female mammals, proper oocyte development is a vital prerequisite for future 
gamete viability and fertility. This development of oocytes, known as oogenesis, 
begins with the migration of primordial germ cells to the genital ridge of the early 
embryo, where multiple rounds of mitotic division occur without complete 
cytokinesis. The result is temporary cyst morphology. Cyst breakdown is a crucial 
process in the next developmental stage, resulting in formation of the single 
oocytes which will grow in follicles surrounded by granulosa cells and eventually 
develop into eggs. These aspects of embryogenesis are conserved across multiple 
species, including Drosophila, mice, and humans. Extensive research has already 
been completed to elucidate the mechanisms through which the steroid hormone 
estrogen regulates these developmental processes. Some research shows that 
progesterone, among other steroid hormones, also plays a role in inhibiting cyst 
breakdown and disrupting proper follicular assembly. However, specific types of 
progesterone receptors (PRs) and the signaling pathways they mediate have not 
yet been studied in the fetal stages of ovarian development. Here, the expression 
of specific PRs has been investigated and assessed via immunocytochemistry. The 
functional characterization of each individual progesterone receptor using organ 
culture is now in early stages of investigation. The experimental results confirm 
the presence of four different types of PRs: PR-A and PR-B, PAQR3, PGRMC1, 
and PGRMC2. Each receptor type shows evidence of expression at different 
stages of development as well as localization to different cell types within the 
ovary. Elucidating the detailed signaling pathways pertaining to each receptor 
requires additional investigation.  
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Introduction 
 
 The reproductive success of all organisms is the most critical element of 
generating off-spring and contributing to the genetic variability of life in general. 
Oogenesis in females is a vital developmental process which determines the 
future reproductive ability of animals by generating viable oocytes for the future. 
Though many fundamental concepts have been studied, this process is not 
completely understood.  
In female mice, oocyte precursor cells known as primordial germ cells 
migrate from the exterior of the embryo into the genital ridge, which will become 
the organism’s reproductive organs. This migration of the cells into the embryo 
occurs at around 10.5 days post coitum (dpc). At the genital ridge, the primordial 
germ cells divide synchronously multiple times by mitosis to form germ-line cysts 
(Pepling and Spradling, 1998). The process results in cysts due to the lack of 
cytokinesis following each individual primordial germ cell’s mitotic replication, 
and intercellular bridges connect the various cells within a cyst and hold it 
together (Fig. 1). 
The germ cells within the multiple clusters of cysts within the ovary are 
known as oogonia at this stage. This process is conserved and also present in 
invertebrate females such as D. melanogaster (De Cuevas et al., 1997). At around 
13.5 dpc, the oogonia begin to undergo meiotic division and are known as 
oocytes. The oocytes arrest at prophase I of meiosis, which will allow for 
homologous recombination of the chromosomes via the formation of the  
 
 
Figure 1. Timeline of germ cell development in the mouse and stages leading to 
oocyte development and 
in green; granulosa cells are shown in red (adapted from Pepling, 2006).
 
synaptonemal complex; this is a necessary process which results in increased 
genetic variability. At 17.
oocytes proceed in maturation and begin the process of becoming enclosed in 
single follicles. The cyst breakdown process is a combination of cellular processes 
including cytokinesis, apoptosis, and continuing differentiation of 
into a mature oocyte. 
The proposed explanation for the mechanism of cyst breakdown states that 
cyst breakdown is a cumulative effect of these several processes. Many of the 
oocytes within the cyst undergo apoptosis and die, which results in 
maturation. Precursor germ cells and oocytes are shown 
5 dpc, the cyst starts to undergo breakdown as the 
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the germ cell 
a disassembly 
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of the cyst. In fact, nearly two-thirds of the oocytes die at around this time, 
leaving only about one third of the original number of oocytes to become 
enclosed in granulosa cells and then mature into primordial follicles (Pepling and 
Spradling, 2001). Granulosa cells are a type of somatic cell within the ovary 
which are usually found surrounding single oocytes. It is possible that the 
granulosa cells serve a nursing function for the particular oocyte that they enclose 
(Fig. 2).  
 
 
Figure 2. Diagram of the cellular layout within the ovary. Oocytes were labeled 
with Stat-3 (green), a marker specific for a protein in the oocyte cytoplasm. All 
cell nuclei were labeled with propidium iodide (red), a DNA intercalating agent. 
 
 
In mice, the numerical statistic of this process is quiet large. Out of around 
6,000 initial germ cells, only around 2,000 germ cells survive following cyst 
breakdown for assembly into primordial follicles. In human females, the same 
process takes place and the number of oocytes remaining following cyst 
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breakdown is equivalent to around 2 million oocytes out of an original 7 million 
germ cells (Baker, 1963). The number of a female’s oocytes steadily decreases 
during her life span, and after a certain age, the quality of her oocytes also begins 
to decrease. This occurs for a few decades until the period known as menopause, 
by which time the oocyte pool is largely depleted. 
The process of cyst breakdown has many unanswered questions. The need 
for such a significant amount of apoptosis is unclear, although current theory 
suggests that this wide-spread apoptosis in the ovary is actually a critical element 
for completion of cyst breakdown (Greenfield et al., 2007). Based on recent 
research, it is known that exogenous neonatal treatment of ovaries with steroid 
hormones such as estrogen and mimics such as estradiol and genistein can prevent 
proper cyst breakdown; this prevention inhibits the proper assembly of oocytes 
into single follicles and results in infertility (Chen et al., 2007; Jefferson et al., 
2002). Other remaining questions regarding this process concern the selection of 
the oocyte’s fate for survival or apoptosis. It is not known if there is a specific 
signal, pathway, or reason to label certain oocytes for apoptosis. Even more so, 
the exact signals for regulation and coordination of cyst breakdown are not all 
identified. In the female mouse, germ cell death and cyst breakdown are 
completed about three to four days after birth; in the human female, this process 
occurs just before birth. The oocytes which successfully assemble into primordial 
follicles are single cells which are enclosed and surrounded by a layer of 
granulosa cells. These remaining germ cells become the limited number of 
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gametes the female can use for sexual reproduction over the course of her life 
time. Essentially, this is the source of fertility.  
Beyond the presented timeline of neonatal germ cell development, the 
primordial follicles continue to mature as gametes. At puberty, various hormones 
stimulate the follicle to undergo folliculogenesis (Matzuk et al., 2002). The 
oocyte within the follicle progresses through a primary, secondary, and tertiary 
stage of growth and development. The primordial follicle develops into a primary 
follicle when the granulosa cells surrounding the oocyte take on a cuboidal shape. 
Continued growth and division of the granulosa cells into multiple layers 
surrounding the developing oocyte leads into the secondary follicle stage. At this 
stage, an additional layer of theca cells envelops the exterior of the follicle as a 
whole, surrounding the granulosa cells. The follicle then proceeds through an 
extra tertiary stage of growth into the preovulatory stage. 
Complete development of the oocyte through all of the stages prepares it 
to be finally released during ovulation, when the oocyte is officially an ovum (or 
egg). The ovum is fully functional and competent to be fertilized by sperm. 
Penetration by sperm finally completes the process of meiosis in the ovum which 
had begun when it was still only a germ cell in a dividing cyst. Successful 
fertilization of the ovum is followed by implantation in the female’s uterus and 
generation of a new and unique organism.  
 The importance of researching the processes of germ cell development and 
oocyte maturation cannot be underestimated. Infertility is a problem which can 
result when oocytes are not properly developed and assembled within the ovary. 
7 
 
What is unfortunate is that in humans, follicular assembly occurs a few months 
before the time of birth; however, infertility may not be diagnosed until two, 
three, or even four decades later. According to the Centers for Disease Control 
and Prevention, 7.3 million females of reproductive age are infertile in the United 
States. This accounts for almost 12% of the female population at reproductive age 
(Chandra et al., 2006). Even more significantly, there has been a notable increase 
in this statistic over the past few decades, which coincides with an exponential 
increase in the number of industrial compounds in use (Stephen and Chandra, 
1995). 
Besides the fact that the population size has obviously increased in the 
past few decades, there are possibly less obvious factors involved in this increased 
occurrence of infertility. As mentioned previously, estrogen plays a critical role in 
the proper development of the oocytes and the ovary as a whole. It is important to 
notice that the amount of exogenous estrogens in the environment has been 
increasing, and there appears to be a correlation between this trend and increased 
infertility rates among female mammals. There are both naturally-occurring as 
well as synthetic chemical compounds which are very similar to estrogen in 
structure and mimic its activity via the estrogen receptor.  
Exposure to elevated levels of these exogenous estrogenic compounds 
during the critical stages of neonatal development can result in various defects 
within the ovary, one of which is the presence of multiple oocyte follicles 
(MOFs). Rather than follicles forming properly with a single oocyte enclosed 
within layers of granulosa cells, MOFs contain two or more oocytes enclosed 
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within a follicle. The MOF appears to be the product of a cyst which did not break 
down completely. Observation of adult female mouse ovaries that had been 
treated as neonates with estrogen, estradiol, or other estrogen mimics such as 
bisphenol-A or diethylstilbestrol shows a higher percentage of MOFs and a lower 
percentage of single oocytes when compared to control mice (Suzuki et al., 2002). 
Additional compounds such as genistein and progesterone (P4) exhibit similar 
effects on the developing ovary when present in excessive amounts (Chen et al., 
2007). Many of these are not uncommon industrial compounds and their presence 
in manufactured products such as plastics or polycarbonates may be altering the 
natural hormonal composition of mammals exposed to these products (Fig. 3). 
 
 
Figure 3. Examples of natural hormones and mimicking synthetic compounds: 
estrogen (A), estradiol (B), genistein (C), progesterone (D), diethylstilbesterol (E), 
bisphenol-A (F).  
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 The steroid hormone estrogen and its receptors in particular have been the 
focus of extensive research in understanding the normal mechanisms of germ cell 
development and the possible complications or disruptions in the mechanisms 
involved. Estrogens can signal through two classic nuclear receptors, estrogen 
receptor (ER) α and ER β (Pettersson and Gustafsson, 2001). These receptors 
have already been studied meticulously for many years, and their characterization 
continues to develop today. Double knockout female mice missing both receptors 
are infertile, as are ER α knockout mice (Lubahn et al., 1993). ER β knockout 
mice exhibit reduced fertility (Krege et al., 1998; Hewitt et al., 2000). 
The fragility of development can be deduced from this research. Estrogen 
is vital for proper development of an embryo’s reproductive organs and for future 
reproductive viability. Mice lacking estrogen receptors are infertile, but treatment 
of neonatal female mice with levels of estrogen which are higher than normal also 
results in reduced fertility due to the formation of MOFs. Because of this effect in 
mice, it is hypothesized that in the fetal stage, the substantial amount of 
circulating maternal estrogen (relative to the embryo) inhibits cyst breakdown 
before birth (Chen et al., 2009). The significant decrease in estrogen levels at 
birth and afterwards allows for cyst breakdown to take place and for oocyte 
assembly into primordial follicles to take place. Therefore, treatment of ovaries 
with estrogenic compounds in the lab or exposure of ovaries to these compounds 
in the environment may continue to inhibit cyst breakdown and oocytes will not 
form properly.  
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Estrogen is only one of multiple factors in the developmental processes 
being described. Research results have provided a glimpse of the great complexity 
found in estrogen receptors. For example, the ERs can even bind ligands other 
than estrogen. ER β can also bind and mediate the effects of genistein, a 
compound normally found in plants (Jefferson et al., 2002). Many other hormones 
and their receptors mediate their own designated pathways and together they all 
culminate into an integrated network of signaling cascades, transcription 
regulation, and phenotypic responses. 
Progesterone is another steroid hormone which has been considered in 
more current research, but not nearly as extensively in regards to oocyte 
development as compared to the efforts of estrogen receptor research. Together 
with estrogen and other hormones, progesterone regulates and coordinates the 
continuous cycles of the reproductive system such as menstruation (Conneely et 
al., 2003). Progesterone is a vital hormone involved in processes throughout a 
female’s lifetime: oogenesis, ovulation, pregnancy, and menopause. It is produced 
mainly in the ovaries, but a few other tissues such as the adrenal cortex produce 
progesterone as well. 
During menstruation, developing follicles in the ovaries secrete estrogen 
and progesterone to thicken the lining of the uterus and to induce the 
endometrium to secrete proteins in preparation of possible zygote implantation. 
After ovulation of an ovum, progesterone levels continue to increase in the 
reproductive system due to its secretion by the corpus luteum cells, which are 
formed from the tissue of the remaining follicle after release of the ovum. 
 
Following fertilization and implantation, the placenta takes on the role of 
producing progesterone to maintain pregnancy, and t
progesterone also suppress ovulation during that time.
As a side note, it is important to mention that a synthetic molecule known 
as progestin is currently of particular interest in research due to its useful function 
in oral contraceptives, but possibly detrimental role in increasing risk of breast 
cancer. Progestin was purposefully synthesized to be used as a drug and function 
as a progesterone mimic (Fig. 4). It is known to bind to some progesterone 
receptors in the body, but not n
are considered to be more potent than those of progesterone.
 
 
 
Figure 4. Structure of progesterone steroid hormone (A) and structure of a 
synthetic progestin molecule (B).
 
 
Estrogen has been shown to p
cancer (Holmberg 
conclusive. Females undergoing estrogen and progestin hormone replacement 
he elevated levels of 
 
ecessarily all of them, and the effects of progestin 
 
 
lay a large role in development of breast 
et al., 2008).The roles of progesterone and progestin are less 
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therapy have an increased risk of breast cancer, the breast cancer tumors are 
larger, and the breast cancer overall has more fatal consequences. Progestin, as a 
ligand bound to a receptor, plays a role by specifically regulating certain 
microRNA (miRNA) levels in cells (Cochrane et al., 2012). It has also been 
shown to stimulate expression of growth factors, influence cell-cycle control, and 
induce expression of protooncogenes (Pasqualini et al., 1998). While more and 
more research is being dedicated to studying progestin, much of the data being 
currently obtained in regards to its overall effects and risk is inconclusive or 
contradictory. On the other hand, progesterone has been shown to have an 
inhibitory effect on breast cancer and prevent the proliferation of breast cancer 
cells (Formby and Wiley, 1998). It appears that these two seemingly similar 
compounds have opposing functions and it is important to continue research on 
progesterone and progestin, their receptors, and their signaling pathways to 
determine their mechanisms of action. 
Progesterone itself can signal via multiple types of progesterone receptors 
(PRs), and its effects during embryogenesis are similar to those of estrogenic 
compounds. Developing ovaries are naturally exposed to and need specific levels 
of maternal progesterone, but further treatment of neonatal ovaries by elevating 
the levels of progesterone blocks cyst breakdown (Chen et al., 2007).  
Progesterone can be converted to estrogen within the body, so a 
nonmetabolizable form of progesterone known as promegestone has also been 
utilized in organ cultures to verify whether the effects of progesterone are direct 
or indirect. Organ cultures treated with promegestone also resulted in inhibition of 
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cyst breakdown and follicle assembly, which is evidence that progesterone does 
have an important and direct effect on oogenesis. Previous research also shows 
that estrogen might be a slightly more potent inhibitor of cyst breakdown as 
compared to progesterone; ovaries cultured from PND 1-8 with progesterone 
showed a decrease in percent single oocytes (68%) when compared to control 
cultured ovaries, which had 86% single oocytes (Chen et al., 2007).  Ovaries 
cultured from PND 1-8 with estrogen had only 53% single oocytes. Significantly, 
treatment of ovaries with both progesterone and estrogen showed an additive 
effect resulting in only 34% single oocytes.  
Progesterone can signal through two known nuclear receptors: PR-A and 
PR-B; the use of different promoters results in both receptors being isoforms of 
the same gene (Conneely et al., 1989; Kastner et al., 1990). Progesterone 
signaling can also occur at the membrane; for example, a nuclear isoform may 
translocate to the membrane. In the family of progestin and AdipoQ receptors 
(PAQR), PAQR3 is a seven transmembrane spanning receptor which may bind 
progesterone. Progesterone receptor membrane component 1 (PGRMC1) and 
PGRMC2 also act as PRs (Peluso, 2006). 
 A goal of this research is to begin investigating PRs with greater intensity. 
Due to the scarcity of research information available on PRs and their role in 
neonatal reproductive organ development, this preliminary research begins with a 
straight forward approach and basic questions: which specific PRs are present in 
the neonatal ovary, and which specific cell types are expressing these receptors. 
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 An elementary amount of information is available regarding each of the 
four PRs mentioned. PR-A and PR-B are nearly identical isoforms of the human 
progesterone receptors (PR) gene. The two isoforms have 780 identical residues, 
but PR-B contains an additional 164 residues on the N-terminal polypeptide end 
(Tung et al., 2006). Ligand-bound PR-B is also the stronger regulator of 
transcription, and functionally, both isoforms regulate the expression of different 
genes. A PR polyclonal antibody was used to identify both isoforms 
simultaneously in this project.  
While expression of PR-A and PR-B in most normal tissues (generally on 
breast tissue and reproductive organs) is equimolar, the ratio of the two isoforms 
is not consistent in tumors, particularly in breast cancer (Sartorius et al., 2003). 
An important factor to consider is that PR-A and PR-B both serve as inhibiting 
regulators of ER mediated transcription, but they do so via two different 
mechanisms, due to their different regulatory functions. The PR isoform 
composition of the tumor may therefore influence hormonal therapy targeting the 
tumor. Unfortunately, however, clinical assays are not currently capable of 
distinguishing one specific isoform from the other. These receptors have therefore 
had significant implications in the study of breast cancer. In this research, an 
alternate evaluation of PR will begin in regards to its role in development of the 
reproductive organs. Both of the PR isoforms have already been identified in the 
granulosa and theca cells of adult ovaries (Gava et al., 2004). 
The PAQR family of seven transmembrane spanning (7TM) receptors is 
produced from a total of 11 different genes (Tang et al., 2004). The individual 
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receptors bind a variety of ligands. Even though the entire family has been 
identified recently, the receptors appear to be highly conserved with homologs 
found even in eubacteria. The discovery of these seven transmembrane domain G-
protein-coupled receptors in 2003 was considered a significant breakthrough 
(Fernandes et al., 2008). This is because progesterone and its derivatives were 
already in use for treatment of various disorders related to the reproductive 
organs, and the discovery of these receptors introduced a possibly new therapeutic 
target in treatment. This family of receptors is currently being evaluated for a 
possible role in mediating progesterone signaling and exhibiting anti-tumorigenic 
effects in ovarian cancer. It is thought that pharmacological activation of these 
types of receptors which mediate anti-tumorigenic responses may be useful in 
developing cancer treatments. 
PAQRs 7, 8, and 5, also known as mPRs α, β, and γ respectively, have 
already been identified as membrane progestin receptors (mPRs), with the 
PAQR7 isoform being predominant in reproductive tissues (Tang et al., 2004). 
PAQR7 has also been identified as a membrane progesterone receptor in trout 
(Charles et al., 2010). Initial studies showed that PAQR7 was localized to the 
oocyte membrane, but later studies concluded that the receptor was in fact 
localized to the endoplasmic reticulum of oocytes (Fernandes et al., 2008).  
Regarding the breakthrough in 2003 and the discovery of these receptors, it was 
shown that injection of mPR antisense oligonucleotides into zebra fish inhibited 
oocyte maturation, which is proof that these receptors are involved in promotion 
and regulation of proper oocyte maturation (Zhu et al., 2003). Very little detail is 
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known otherwise regarding the functional activity and mechanisms of the 
different PAQRs, however. PAQR3 does not seem to have been assigned a 
specific role yet (Tang et al., 2004). In this research, PAQR3 is shown to exhibit 
expression in the ovary localized to the cytoplasm of the oocytes a few days after 
birth; it is likely that it can mediate the effects of progestin and possible that it can 
mediate the effects of progesterone as well. Specific localization to the 
endoplasmic reticulum was not noted in this case. Due to the likelihood that 
PAQR3 mediates the effects of progesterone, PAQR3 will be considered as a 
progesterone receptor. 
One of the PRs receiving the most attention in current research is 
PGRMC1. Its expression is localized to intracellular membranes, the cytoplasm, 
and the nucleus, particularly in the ovary and the liver (Lösel et al., 2008). 
However, its expression shows significant variability and may be due to 
dependence on factors such as the cell cycle. It is currently undecided whether or 
not PGRMC1 functions as a dimer, although it may instead be forming a 
functional complex with another protein; different experiments are contradictory 
(Falkenstein et al., 2001; Lösel et al., 2008). The selectivity and affinity of 
PGRMC1 for progesterone is higher compared to all other possible steroid 
ligands, and it is has been discovered that PGRMC1 is a receptor that serves an 
important role in mediating progesterone’s anti-apoptotic effect (Peluso et al., 
2007). Overexpression of the receptor results in enhanced responsiveness to 
progesterone, whereas an antibody to PGRMC1 inhibits progesterone’s anti-
apoptotic action (Peluso et al., 2008). 
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PGRMC1 also appears to have a great variety of other properties and 
functions. For example, PGRMC1 expression is increased in conditions of low 
oxygen, the mechanism for which is still unknown (Hughes et al., 2007). 
Although an exact function for PGRMC1 in other cells has not yet been 
elucidated, it is hypothesized that the receptor may play a role in the regulation of 
cholesterol and steroid synthesis in cells that are steroid generating, such as 
granulosa cells (Peluso et al., 2008).In granulosa cells, PGRMC1 is localized to 
the plasma membrane, the cytoplasm, and the nucleus. The nuclear localization 
suggests that PGRMC1 is involved in gene expression regulation. Therefore, it is 
likely that PGRMC1 is important for proper reproductive organ development and 
viability.  
Interestingly, PGRMC1 is consistently expressed in most cells of ovarian 
tumors and promotes the survival of the normal cells as well as the tumor cells. 
PGRMC1-depleted ovarian cancer cells were found to promote apoptosis and 
form tumors less often when introduced into mice. Any tumors that did form were 
generally smaller in size as compared to normal tumors, with an average decrease 
in size being about 75% (Peluso, 2011). This indicates that PGRMC1, like 
PAQRs, could be a critical target of gene therapy for the treatment of ovarian 
cancer.  
 A receptor closely related to PGRMC1 is PGRMC2. However, very few 
papers have been published in the past few years mentioning this receptor. Most 
of the currently existing data on PGRMC2 only states that PGRMC2 (along with 
PGRMC1) exhibits expression in rat ovaries, and some minor structural 
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characterization of the PGRMC2 receptor has taken place (Cahill, 2007). 
However, PGRMC2 expression can be evident on many other cell types within 
humans in an almost ubiquitous manner, excluding a few specific tissue types 
such as adipose tissue (Chen et al., 2010). Whether or not this receptor plays a 
role in proper oocyte development and follicular assembly is not currently known 
and will be investigated here.  
So far, the obtained results suggest that PGRMC2 is expressed earlier on 
while the oocytes are still in the cyst stage, at around 13.5 dpc to PND 1. The 
receptors PGRMC1 and PAQR3 do not appear to be expressed until the latest 
stages of cyst breakdown and as late as PND 7 in the case of PAQR3. PR-A and 
PR-B expression occurs in both the early and later stages of development.  
 
Materials and Methods 
 
Animals 
 
The C57BL/6 (B6) inbred strain of mice, supplied by Jackson Labs, was 
used for the experiments. The animals were maintained by the lab animal resource 
facility at Syracuse University.  B6 females were mated with males weekly and 
impregnation was evaluated by checking for vaginal plugs in the females daily. 
Matings were set up on Mondays after 2:00pm and females were checked for 
vaginal plugs every morning before 10:00am for the following four days. Females 
with plugs were then isolated and marked as 0.5 dpc, estimating that conception 
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occurred at around midnight. Pregnant females gave birth at around 19.5 dpc, at 
which time the litter age was marked post natal day 1 (PND1). 
 
Dissection 
 
Animals collected for experiments ranged in age from 13.5 dpc to PND 7. 
Fetal animals were obtained by euthanizing the pregnant female with carbon 
dioxide and dissecting the fetal pups from her abdomen. Pregnant females were 
euthanized using the Euthenex Equipment manufactured by E-Z Systems. 
Neonatal litters were collected from the female’s cage. The litters were dissected 
using a Nikon SMZ1500 dissecting microscope in 1x phosphate buffered saline 
(PBS) solution. The ovaries were removed from the female and incubated in a 
“fix” solution composed of 200:400µL 16% formaldehyde (from Ted Pella Inc.) 
to 1x PBS, for a final dilution of 5.3% formaldehyde. This solution was used to 
preserve the ovaries for 24 hours on the nutator at 4 °C. The incubated tubes were 
labeled with the tissue collected, age of the organism, date of dissection, and 
antibody to be used for staining.  
 
Whole Mount Antibody Staining of Neonatal Ovaries 
 
The ovaries were prepared for indirect antibody staining following a 
protocol specifically developed for whole mount antibody staining of fetal mouse 
gonads. Following preservation in fix, the ovaries were washed twice in 1 mL of 
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PT (1X PBS/0.1% Triton X-100) and then incubated in 1 mL of PT on a nutator 
for at least 30 minutes. The ovaries were then incubated in 1 mL of PT + 5% 
bovine serum albumin (BSA) on a nutator for at least 30 minutes. For incubation 
with the primary antibody, the ovaries were incubated with 5 µL of primary 
antibody diluted in 500 µL of PT + 5% BSA for 24 hours on the nutator at 4 °C 
(Table 1). At this time, the secondary antibody was also prepared for later use. 
This required 2.5µL of fluorescent secondary antibody (Alexa Fluor 488) to be 
pre-absorbed with embryo powder (ground pellets from homogenized PND 12.5 – 
14.5 mouse embryos incubated in ice-cold acetone and centrifuged at 10,000 g) 
and diluted in a tube with 500 µL of PT + 5% BSA, wrapped in aluminum foil, 
and incubated for 24 hours on the nutator at 4 °C (Table 2).  
 
Table 1 
Primary antibodies used in whole mount antibody staining 
Antibody  Description Amount used (diluted in 
500 µL PT+5% BSA) 
PR (Santa Cruz 
Biotechnology) 
labels PR-A and PR-B 
progesterone receptors 
5 µL 
PAQR3 (Santa Cruz 
Biotechnology) 
labels PAQR3 receptor 5 µL 
PGRMC1 (Santa Cruz 
Biotechnology) 
labels PGRMC1 receptor 5 µL 
PGRMC2 (Santa Cruz 
Biotechnology) 
labels PGRMC2 receptor  5 µL 
Stat-3 (Santa Cruz 
Biotechnology) 
oocyte marker  1 µL 
Vasa (Santa Cruz 
Biotechnology) 
germ cell marker  2 µL 
 
 The following day, the ovaries were washed in 1 mL of PT + 1% BSA for 
at least 30 minutes on the nutator at room temperature. Then they were incubated 
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with 10 µL of RNase A (10 mg/mL RNase A) diluted in 1 mL PT + 1% BSA and 
placed on the nutator for 30 minutes at room temperature. RNase A is a reagent 
used to hydrolyze chains of ribonucleotides in tissue. After 30 minutes in RNase 
A, the ovaries were incubated with 10 µL of propidium iodide (0.5 mg/mL, 
Molecular Probes) diluted in 1 mL PT + 1% BSA, wrapped in aluminum foil, and 
placed on the nutator for 20 minutes at room temperature. Propidium iodide is a 
DNA intercalating agent which fluoresces when excited by light with a 
wavelength of 488 nm. The tube of ovaries stayed wrapped with aluminum foil 
from this point on to the end of the staining procedure to prevent loss of reagent 
fluorescence. After 20 minutes, the ovaries were washed in PT + 1% BSA on the 
nutator for at least 30 minutes at room temperature. Then, the ovaries were 
incubated with the secondary antibody solution prepared the previous day. The 1 
mL of PT + 1% BSA was pipetted out of the tube of ovaries, and the dilution of 
secondary antibody was added to the tube of ovaries, after the embryo powder 
was allowed to sediment out of the secondary antibody preparation. The ovaries 
were incubated with the pre-absorbed fluorescent secondary antibody on the 
nutator for 24 hours at 4°C. 
Table 2 
Secondary antibodies used in whole mount antibody staining 
Antibody  Wavelength Description Amount used 
(diluted in 500µL 
PT+5% BSA) 
goat anti-rabbit 
(Molecular Probes) 
Alexa 488 used to label PR-A 
and PR-B 
2.5 µL 
donkey anti-goat 
(Molecular Probes) 
Alexa 488 used to label 
PAQR3, PGRMC1, 
PGRMC2 
2.5 µL 
donkey anti-goat 
(Molecular Probes) 
Alexa 568 used to label 
PGRMC2 
2.5 µL 
22 
 
The following day, the ovaries were washed three individual times with 1 
mL of PT + 1% BSA, each wash for at least 30 minutes on the nutator at room 
temperature. They were then washed with 1 mL of PBS. About 500 µL of PBS 
was then pipetted out of the tube with the ovaries, while the other 500 µL was left 
as solution for the ovaries. A large pipette tip was cut to widen the opening at the 
tip, and the altered tip was used to pipette the ovaries from the tube to the glass 
slide (Fisher Scientific) for preparation. The PBS was completely removed from 
the ovaries on the slide, and about 2 drops of VectaShield (Vector Laboratories) 
were added to the ovaries on the slide for preservation of fluorescence in the dye 
and in the secondary antibody. A coverslip (Corning) was placed over the ovaries 
and after sealing the slide with nail polish, the slide was labeled with the tissue 
stained, the age of the litter, the date of dissection, the primary antibody used for 
staining, and the initials MND. The slides were allowed to dry at room 
temperature in the dark for about ten minutes and then placed into slide holding 
booklets (Fisher) for storage at -20 °C.  
 
Confocal Microscopy 
 
Prepared slides were observed on the Zeiss LSM 710 Confocal 
Microscope in the Blatt Image Center of Syracuse University’s Life Sciences 
Complex. The ovaries were observed under magnifications of 10x, 20x, and 63x 
with oil. With confocal microscopy, the ovaries may be analyzed for expression 
of the labeled protein. The oocyte development stages may be monitored as well. 
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Images were captured on a computer connected to the confocal microscope using 
Zen software and standard magnification conditions: 63x with oil. The images 
were then saved to a data disc and transferred to an LSM Image Browser program 
for editing. 
 
Organ Culture 
 
An additional experiment was performed which allowed for the treatment 
and manipulation of ovarian growth in vitro before staining to observe the effects 
of the treatment. Prior to the dissection of the ovaries, the organ culture media 
was prepared (Chen et al., 2007). All equipment and surfaces, including gloves, 
were sterilized with alcohol before starting the procedure. Materials must also be 
autoclaved (sanitization through cycles of high temperature and pressure) 
occasionally as an extra precaution in sterility. Stock (control) media was 
prepared in a 50 mL falcon tube according to the recipe using 0.5 mL D-MEM 
(Invitrogen) / HAM’s F12 Media with 0.1% BSA, 0.1% Albumax 5X ITS-X, and 
10 mg of L-ascorbic acid (0.05 mg/mL). Treatment media could be made using a 
few microliters the treatment antibody diluted in a few milliliters of transferred 
stock media, generally 25 µl antibody to 2.5 mL stock media. At least three hours 
prior to the start of the dissection, the organ culture incubator (VWR) was sprayed 
with alcohol, turned on, and set to 37 °C and 5% CO2. All of the equipment and 
the removable shelves were placed under a UV light hood (The Baker Company) 
for at least 60 minutes prior to use. After the incubator equilibrated to culture 
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conditions, a sterilized water pan was filled with autoclaved Millipore water and 
placed at the bottom of the incubator. Millicell floating filters for the organ 
culture were cut into culture well-size pieces and stored in a small petri dish under 
the UV light as well. Immediately preceding the dissection, the well plate (BD) 
used for the organ culture was prepared with 400 µL of the control media or the 
treatment media pipetted into each individual, labeled well. One floating filter 
was placed atop the media in each well. The culture plate was then placed in the 
incubator to equilibrate while the ovaries were being dissected.  
Ovaries were dissected from the female mice in Hank’s Balanced Salt 
Solution and collected in a plate filled with the Hank’s Solution. The plate was 
kept in a covered container of ice. During dissection, extra care was taken to 
detach all the surrounding mesonephrous tissue from around the ovaries so that 
the organ was entirely removed from the organism. Once all of the ovaries are 
collected, they were transferred to the culture wells for incubation. Each ovary 
was individually scooped up with watchmaker’s forceps, transferred to a second 
pair of forceps while wiping the first set on a kimwipe, and then transferred back 
to the first pair of forceps to remove all of the Hank’s Solution from the ovary. 
Under a microscope (Zeiss), the ovary was then transferred from the tip of the 
forceps to the floating filters in the well plates. Two to three ovaries were placed 
per filter in a well. A drop of media was then placed on each ovary using forceps. 
This sequence was repeated with each ovary from a dissection. The well plate was 
then placed in the incubator and incubated at around 37 °C with 5% CO2 for at 
least 24 hours up to a few days, depending on the purpose of the experiment. 
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The culture media was replaced each day. All of the equipment used was 
sprayed with alcohol and placed under UV light for at least 30 minutes prior to 
each replacement. The old media was then drawn out from under the filter, and 
400 µL of new control or treatment media was added to each well, taking care not 
to submerge the filters. A fresh drop of media was also placed on each ovary 
using forceps. Replacements were completed using similar conditions in regularly 
spaced 24 hour intervals.  
Once the ovaries were cultured for a specified number of days, they were 
removed from the filters and incubated in tubes of fix solution (200:400µL 16% 
formaldehyde to 1x PBS) for 24 hours on the nutator at 4 °C for preservation. The 
control ovaries were collected together in one tube, and the treated ovaries were 
collected together in a separate tube. The incubated tubes were labeled with the 
tissue collected, age of the organism during the time span of the organ culture, 
date of organ culture completion, and antibody to be used for staining. The 
standard whole mount antibody staining protocol was then used to stain the 
cultured ovaries for observation of treatment results. 
 
Counting Follicle Development 
 
 When performing an experiment where both quantitative and qualitative 
changes are expected, there must be standardized methods of analysis to 
determine and characterize the results. An expected result when performing organ 
culture experiments with ovaries is that the number of oocytes present and their 
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morphology will change. One way to quantify this result is to count follicle 
development.  
Counting follicle development is a dependable and standardized method of 
interpreting immunocytochemistry results. The numbers of oocytes per section are 
counted and then the percent of cyst breakdown can be calculated based on the 
statistics obtained. Therefore, oocytes or follicles can be counted and compared 
among other samples in a standardized way. Counting follicle development was 
not performed in the research described here. Because most of the experimental 
data is from simple stains of tissue which has not undergone treatment, this 
method has no relevant application. The last two experiments mentioned were 
performed recently and do include manipulation of the ovary environment. The 
counting follicle development method will need to be applied in the near future to 
analyze the results of these two organ cultures as well as future organ culture 
experiments.  
 
Results 
 
Receptors PR-A and PR-B are expressed in the developing neonatal ovary 
 
To determine which cell types express progesterone receptors PR-A and PR-B in 
developing neonatal ovaries, immunocytochemistry was performed for 15.5 and 
17.5 dpc, as well as PND 1, 3, 5, and 7 (Fig. 5). 
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Figure 5. Expression of PR-A and PR-B progesterone receptors in neonatal 
mouse ovaries. Confocal sections show evidence of labeling with PR antibody 
(green) at 15.5 dpc (A), 17.5 dpc (B), and PND 7 (F). Cell nuclei were labeled 
with propidium iodide (red).    
 
 
Moderate expression of the PR-A and PR-B progesterone receptors was 
detected in the developing neonatal ovary, as evidenced by 
immunocytochemistry, at 15.5 – 17.5 dpc, as well as PND 7 (Table 3). Expression 
during 15.5 – 17.5 dpc was evident in the cytoplasm of multiple cell types in the 
ovary, including oocytes and granulosa cells. Particularly at 17.5 dpc, expression 
of PR-A and PR-B seems to indicate an interesting result that the receptor may be 
localized to certain organelles within the oocyte. This hypothesis is due to the fact 
that the brightest spots of fluorescence are present in sections bordering almost all 
of the round oocyte nuclei. It is also possible that PR-A and PR-B function as 
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nuclear membrane receptors. Weak expression at PND 7 was limited mainly to 
the cytoplasm of the oocytes. 
 
Table 3 
Summary of PR-A and PR-B Expression 
Age 15.5-17.5 dpc PND 1-5 PND7 
Location  cytoplasm of oocytes 
and granulosa cells, 
may be localized at 
17.5 dpc 
 
――― cytoplasm of oocytes 
Level of 
expression over 
moderate expression insignificant 
expression 
 
weak expression 
 
 
Receptor PAQR3 is expressed in the developing neonatal ovary 
 
To determine which cell types express progesterone receptor PAQR3 in 
developing neonatal ovaries, immunocytochemistry was performed  for 15.5 and 
17.5dpc, as well as PND 1, 3, 5, and 7 (Fig. 6). 
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Figure 6. Expression of PAQR3 progesterone receptor in neonatal mouse ovaries. 
Confocal sections show evidence of labeling with PAQR3 antibody (green) at 
PND 7 (F). Cell nuclei were labeled with propidium iodide (red).    
 
There does not appear to be significant expression of the PAQR3 receptor in the 
developing neonatal ovary until PND 7. On PND 7, the PAQR3 receptor shows 
strong expression specifically localized to the cytoplasm of the oocytes (Table 4). 
 
 
Table 4 
Summary of PAQR3 Expression  
Age 15.5 dpc – PND 5 PND 7 
Location  ――― cytoplasm of oocytes 
Level of expression  insignificant expression strong expression 
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Receptor PGRMC1 is expressed in the developing neonatal ovary 
 
To determine which cell types express progesterone receptor PGRMC1 in 
developing neonatal ovaries, immunocytochemistry was performed for 15.5 and 
17.5dpc, as well as PND 1, 3, 5, and 7 (Fig. 7). 
 
Figure 7. Expression of PGRMC1 progesterone receptor in neonatal mouse 
ovaries. Confocal sections show evidence of labeling with PGRMC1 antibody 
(green) at PND 3 (D), PND 5 (E), and PND 7 (F). Cell nuclei were labeled with 
propidium iodide (red).   
 
 
 
Moderate expression of the PGRMC1 progesterone receptor was detected 
in the developing neonatal ovary, as evidenced by immunocytochemistry, at PND 
3 – PND 7 (Table 5). During this age, PGRMC1 is expressed in the cytoplasm of 
both oocytes and granulosa cells. A significant amount of background staining 
exists for most of the samples, and ovaries at 17.5 dpc and PND 1 only showed 
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random background staining with little localization or specificity of the antibody. 
PGRMC1 antibody labeling at PND 3 appears moderate, but somewhat diffuse. 
Overall, the evidence of expression appears across multiple cell types. Labeling of 
oocyte nuclei with PGRMC1 antibody is also apparent. 
 
 
Table 5 
Summary of PGRMC1 Expression  
Age 15.5 dpc – PND 1 PND 3-7 
Location  ――― cytoplasm of oocytes and 
granulosa cells, possible 
labeling of oocyte nuclei 
 
Level of expression  insignificant expression moderate expression 
 
 
Receptor PGRMC2 is expressed in the developing neonatal ovary 
 
To determine which cell types express progesterone receptor PGRMC2 in 
developing neonatal ovaries, immunocytochemistry was performed for 13.5, 15.5, 
and 17.5dpc, as well as PND 1, 3, 5, and 7 (Fig. 8). 
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Figure 8. Expression of PGRMC2 progesterone receptor in neonatal mouse 
ovaries. Confocal sections show evidence of labeling with PGRMC2 antibody 
(green) at 13.5 dpc (A), 15.5 dpc (B), 17.5 dpc (C), and PND 1 (D). Cell nuclei 
were labeled with propidium iodide (red).    
 
Strong expression of the PGRMC2 progesterone receptors was detected in the 
developing neonatal ovary, as evidenced by immunocytochemistry, at 13.5 dpc-
PND1 (Table 6). An additional immunocytochemistry experiment was performed 
for age 13.5 dpc with the PGRMC2 antibody because of the notably strong and 
specific expression observed at 15.5 dpc. Strong expression of PGRMC2 was 
localized to the cytoplasm of the granulosa cells at 13.5 and 15.5 dpc with 
expression levels decreasing slightly approaching PND 1. PGRMC2 labeling at 
PND 3 – PND 7 was extremely diffuse and did not appear to be significant.  
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Table 6 
Summary of PGRMC2 Expression  
Age 13.5 dpc – PND 1 PND 3-7 
Location  cytoplasm of granulosa cells 
 
――― 
Level of expression  strong and slightly 
decreasing over time 
 
insignificant expression 
 
PGRMC2 expression at 13.5 dpc also showed a unique expression pattern 
with strong labeling of the membranes of certain cells characterized by a dense 
nucleus. This dense nucleus is not uncommon for the gonads of early embryos, 
but there are currently no explanations for its unique appearance. 
Immunocytochemistry was then performed with a triple stain to observe 
PGRMC2 expression in relation to the germ cells at 13.5 dpc more closely (Fig. 
9).  
A triple stain was performed for a few reasons. First, labeling with the 
germ cell marker Vasa confirmed that the organ under observation was an ovary 
and not a testis. It can be difficult to differentiate ovaries from testes at 13.5 dpc 
in mice because they haven’t differentiated significantly and can often look very 
similar. Also, it confirmed the previous results and showed that expression of 
PGRMC2 is found on the granulosa cells. The unknown unusual cells were also 
present and labeled with PGRMC2.  
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Figure 9. Expression of PGRMC2 progesterone receptor at 13.5 dpc in neonatal 
mouse ovaries. Confocal sections of ovaries labeled with Vasa (green) (A), 
PGRMC2 labeled with PGRCM2 antibody (red) (B), cell nuclei labeled with 
Toto-3 (blue) (C), and overlay (D) show evidence of PGRMC2 expression in the 
cytoplasm of granulosa cells.  
 
 
 
All four receptors of interest: PR-A and PR-B, PAQR3, PGRMC1, and 
PGRMC2 are therefore expressed within the time frame introduced in Figure 1. A 
diagram of the cumulative expression of these receptors is illustrated in Figure 10.  
Ideally, a more objective approach would be employed in quantifying the 
expression of these receptors. Although it is not completed here, western blots 
could be used to verify the dependability of the results already obtained. Real-
time polymerase chain reaction (RT-PCR) could also be used as an even more 
accurate way to determine the expression patterns of these receptors.  
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Figure 10. Summary diagram of progesterone receptor expression in the female 
mouse ovary from age 13.5 dpc to PND 7. Order of lines follows the sequence of 
the receptors as presented in the text: PR-A and PR-B (pink), PAQR3 (light blue), 
PGRMC1 (red), and PGRMC2 (dark blue). Pictures are included of the first three 
receptors to show that expression by PND 7 is localized to the cytoplasm of the 
oocytes. 
 
 
It is important to notice the trend as the mouse reaches PND 5 and 
afterwards. The expression of three of the four receptors is present. Due to the fact 
that these three receptors are present in the adult ovary as well, it is possible that 
the expression of these receptors begins as early as PND 5 or PND 7 in the pup 
and continues throughout the lifetime of the female. Also, it is an interesting 
result that at PND 7 all of the progesterone receptor expression is localized to the 
cytoplasm of the oocyte.  
 
PR-A and PR-B 
PAQR3 
PGRMC1 
PGRMC2 
 
Effects of blocking PGRMC2 on oocyte development
 
The mechanisms of PGRMC2 signaling were investigated further given the 
receptor’s strong immunocytochemical staining results. An organ culture 
experiment was performed with incubation of neonatal ovaries at 
5. A function blocking antibody was included in the organ culture media (1: 100 
PGRMC2 antibody to media dilution) as a treatment to test the effects of blocking 
PGRMC2 on oocyte development (Fig. 11). 
 
Figure 11. Confocal sections of
PND 5. PGRMC2 antibody treated
propidium iodide (B), and overlay (C). Control ovaries are shown labeled with 
Stat-3 (D), propidium iodide (E), and overlay (F). Oocytes 
3 (green) and cell nuclei (red) were labeled with propidium iodide. 
 
 
 neonatal mouse ovary cultures from PND 1 to 
 ovaries are shown labeled with Stat
were labeled with Stat
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After organ culture treatment and immunocytochemistry preparation, 
ovaries were observed for proper cyst breakdown and follicular assembly, as well 
as oocyte survival. Treatment of 
antibody in the culture media did not appear to have a significant effect on cyst 
breakdown, follicular assembly, or oocyte survival and number
counting follicle development method needs to 
Another organ culture experiment was performed with incubation of 
neonatal ovaries, at the earlier age 15.5 dpc to PND 1. The same concentration of 
PRGRMC2 function blocking antibody was used in the treatment media (Fig. 12).
Figure 12. Confocal sections 
PND1. PGRMC2 
propidium iodide (B), and overlay (C). Control ovaries are shown labeled with 
Stat-3 (D), propidium iod
3 (green) and cell nuclei (red) were labeled with propidium iodide.  
 
 
PND 1 to PND 5 ovaries with PGRMC2 
; however, the 
be applied for verification.
of neonatal mouse ovary cultures from 15.5 dpc to 
antibody treated ovaries are shown labeled with Stat
ide (E), and overlay (F). Oocytes were labeled with Stat
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Results for the second organ culture experiment were inconclusive. The 
first observation was that the Stat-3 antibody did not bind to and label the oocytes 
in the treated ovary as usually expected. Rather, the Stat-3 antibody appeared to 
exhibit generalized non-specific binding throughout the ovary, and specific 
binding was localized to random granulosa cells dispersed throughout the ovary. 
Nonetheless, the propidium iodide staining of the oocyte nuclei showed an 
abundance of oocytes within the ovary. Is it extremely unusual for there to be so 
many oocyte nuclei present without any labeling by Stat-3. The oocytes are easily 
identified by their characteristic round shape compared to surrounding irregularly 
shaped cells, and also by their slightly brighter staining than the surrounding cells.  
Since the ovary does not appear to have died during organ culture (it 
appears to be completely intact), a possible explanation for this unusual result 
could simply be that the organ culture became contaminated during the course of 
the experiment. The control ovaries, however, do not appear to have been 
contaminated and exhibit normal Stat-3 binding. Nevertheless, the control ovaries 
show an abnormality in that there are very few Stat-3 labeled oocytes within the 
ovary.  Another explanation could be that Stat-3 does not label oocytes as early as 
13.5 dpc (Murphy et al., 2005). If this is the case, PGRMC2 inhibition may have 
prevented the oocytes from developing any further. This is a complicated result 
made even less promising by the fact that the control sample size was two ovaries 
and the treatment sample size was one ovary. This was not an ideal sample size 
because it does not allow for much comparison to be made between sample 
ovaries.  
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Therefore, possible explanations for the results obtained in this organ 
culture experiment are contamination (of the treatment culture well, at least), 
inherent abnormalities within the specific litter sample, and possibly but not 
likely―an actual and severe morphological effect of PGRMC2 receptor inhibition 
within the ovary.  It is necessary to repeat this experiment for verification. A 
higher number of sample ovaries for both the control and treatment organ culture 
are required. Additionally, the counting follicle development method would have 
to be applied in the future to quantify the results of the organ culture experiments 
more accurately and precisely.  
  
Discussion 
 
Establishing a viable pool of mature oocytes is an essential prerequisite for 
the fertility of animals. This is a fragile process which begins early on in 
embryogenesis. Many of the most critical steps in development of the 
reproductive organs take place while the organism is still a fetus, as is the case in 
humans. Proper development depends on the reception and transduction of 
hormones, growth factors, and many other types of signal-pathway inducing 
ligands.  
Two hormones, estrogen and progesterone, are shown to have active roles 
in the development of the reproductive organs as well as in the function of these 
organs for the majority of the female’s lifetime. Previous research shows that 
exogenous treatment of ovaries with estrogen and/or progesterone during a critical 
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time period in development when cyst breakdown occurs significantly decreases 
the number of percent single oocytes. This treatment inhibits cyst breakdown 
from occurring properly. The name for the resulting morphological abnormality 
caused by this exogenous treatment is MOFs. Again, even though estrogen and 
progesterone are required for the proper development of ovaries, exogenous 
treatment of ovaries resulting in excessive amounts of these hormones has 
detrimental effects on the future viability of the gametes and the fertility of the 
female.  
Extensive research has already been dedicated to elucidating the estrogen 
signaling pathways and characterization of various estrogen receptors. Compared 
to estrogen, current research results for progesterone receptors regarding these 
same developmental processes are scarce and insufficient. The research described 
here sought to address this problem. Here, we began preliminary investigation of 
progesterone’s role in development by beginning with the basic identification of 
possible receptors for progesterone to signal through to perform its function. 
Our research results showed that the progesterone receptors PR-A and PR-
B, PAQR3, PGRMC1, and PGRMC2 are all expressed in the ovary at some point 
during mouse development between the ages of 13.5 dpc to PND 7.  PR-A and 
PR-B show moderate expression in the cytoplasm of oocytes and granulosa cells 
during 15.5 – 17.5 dpc, and then a lack of expression until they are expressed 
again at PND 7, although to a slightly weaker degree. Also, staining at 17.5 dpc 
may exhibit localization of PR-A and PR-B at that exact age to a certain organelle 
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within the oocyte, possibly the endoplasmic reticulum or nuclear membrane. 
Further experiments are required for confirmation of this result.  
The receptor belonging to the progestin and AdipoQ family of receptors, 
PAQR3, exhibits strong expression in the ovary starting at PND 7. Expression is 
distinctly localized to the cytoplasm of the oocytes. Although a specific ligand for 
PAQR3 has not been identified, it is likely that it can bind progestin and possible 
that it may bind progesterone as well, since multiple other receptors in the PAQR 
family can bind progestin.  
PGRMC1 has already been researched extensively in effort to elucidate its 
significance in ovarian cancer. Here, we found that PGRMC1 expression begins 
at around PND 3 and grows slightly stronger afterwards. It is expressed 
throughout the ovary in the granulosa cells, in the oocytes, and even within some 
of the oocyte nuclei. Unfortunately, staining with the PGRMC1 antibody did not 
present an adequately specific result; results for PND 3, 5, and 7 all appear to 
have significant background staining. Unless the receptor is actually expressed to 
such an ubiquitous degree, more stainings with variation of antibody 
concentration are necessary for confirmation of the results.  
Although it is one of the least researched receptors to date, PGRMC2 
showed the most interesting staining results. PGRMC2 showed strong expression 
as early as 13.5 dpc which decreased through PND 1. Expression was localized to 
the cytoplasm of the granulosa cells throughout the ovary. After PND 1, results 
were mostly background staining and nonspecific. At 13.5 dpc, there was an 
unusual expression pattern of PGRMC2 in that some cells showed extremely 
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dense expression of PGRMC2 on the membrane and within the cytoplasm. These 
unidentified cells were also characterized by a very dense nucleus. While the 
presence of these types of cells with dense nuclei is not uncommon at that age in 
development and has been noted before, the expression pattern of PGRMC2 
localized to some of these types of cells is peculiar and unexplained.  
After identification of these progesterone receptors, their level of 
expression, and their location within the ovary, organ culture experiments were 
performed to elucidate the importance of these receptors and to determine their 
function. Two organ culture experiments with PGRMC2 function blocking 
antibody were performed. Ovaries with anti-PGRMC2 treatment during PND 1 – 
5 did not appear to show any change in formation of primordial follicles and 
percent of single oocytes when compared to ovaries in control organ culture. This 
is an expected result due to the inherent lack of PGRMC2 expression after PND 1, 
as found with prior immunocytochemistry experiments.  
Ovaries with anti-PGRMC2 treatment during 15.5 dpc – PND 1 showed 
inconclusive results. The control ovaries did contain oocytes; however, there were 
a small number of oocytes present. The treated ovaries seemed to contain multiple 
oocytes, based on the presence of many round nuclei which are characteristic of 
oocyte nuclei. However, there was no specific staining of any oocytes by Stat-3, 
which is a widely used oocyte marker. It is unlikely that PGRMC2 inhibition is 
potent enough to induce such an unusual and extreme morphological response in 
the ovary on its own. Possible explanations for this result may be contamination 
of media used for organ culture, death of the ovaries at some point during culture, 
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or a prior defect in the ovaries or dissection technique. Due to the unusual results 
as well as the fact that a very small sample size was used, repeated experiments 
are required for confirmation of PGRMC2’s role during these early ages.  
Based on previous research, there is conclusive evidence that treatment of 
neonatal ovaries with exogenous estrogens and progesterone will inhibit the 
proper breakdown of cysts during neonatal development and result in MOFs 
which are present for the entire lifetime of the organism. Unfortunately, infertility 
usually cannot be diagnosed until many years after cyst breakdown occurs. 
Although there is currently no way to detect possible exposure to exogenous 
compounds in vivo during development, this research is still useful for possible 
future study and development of treatments.   
Firstly, it is naturally essential to understand the fundamental mechanisms 
of embryogenesis. Understanding the proper mechanisms of development is 
imperative to identify what is abnormal later on. Consequently, understanding 
which processes normally occur and how they are disrupted is useful for 
developing proper prevention strategies. For example, identification of certain 
industrial compounds as estrogen mimics which bind to receptors in living tissue 
or as any other disruptors of development that can do so may lead to strict 
regulation and/or prohibition of their use.  
Additionally, identifying the mechanisms of proper oocyte development is 
crucial for some infertility treatments, known as Assisted Reproductive 
Technology (ART). A female under the age of 30 has around a 40% chance of 
becoming impregnated via ART with the use of her own oocytes, rather than a 
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donor’s oocytes (Krisher, 2004). Using a female’s own oocytes and maturing 
them in vitro, known as in-vitro maturation (IVM), is a possible infertility 
treatment which has had very little success as an ART method, but it does show 
promise. This method is not commonly applied clinically; however, this in-vitro 
method has shown success in livestock and other animals (Krisher, 2004). 
Continuing to elucidate the intricate mechanisms of oocyte maturation will allow 
for refinement of oocyte maturation techniques, optimization of culturing 
conditions, and improvement of the rate for successful implantation of the oocytes 
matured in-vitro (Fasano et al., 2012). These ART treatments are dependent on 
understanding the function of various compounds involved in oocyte maturation, 
including steroid hormones and gonadotropins. The refinement of these 
techniques is an active area of research.  
Equally important is the fact that hormone imbalance or misregulation has 
implications in cancer as well. For example, PGRMC1 mediated progesterone 
signaling has been shown to play a role in ovarian cancer (Peluso, 2011). 
PGRMC1 promotes the survival of both normal and cancerous cells in the ovary, 
and its expression is particularly noted on ovarian tumors. The ability of cancer 
cell lines with PGRMC1 levels depleted by more than 80% to undergo mitosis is 
impaired and apoptosis of many cells is induced, which is evidence that PGRMC1 
promotes the proliferation of ovarian cancer cells (Peluso, 2011). One aspect of 
ovarian cancer treatment could therefore be targeting PGRMC1 via gene therapy. 
Clearly, the characterization of PGRMC1 and other progesterone receptors is 
becoming more important as the research and understanding of these receptors 
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progresses. Developing a timeline of expression for these receptors is a useful 
step in determining the mechanisms of development and in identifying the 
problems associated with multiple pathologies. 
 
Future Directions 
 
 Additional experiments are necessary and valuable to verify the results 
obtained so far. Two sets of organ cultures should be completed with function 
blocking antibodies targeting PGRMC1 and PGRMC2, with three different ages 
cultured for each antibody treatment (ages: 13.5 – 17.5 dpc, 15.5 dpc – PND 1, 
and PND 1 – PND 5). The results obtained from using the antibody treated culture 
media could provide data on the importance of progesterone during this critical 
period of gamete development and the role that the progesterone receptors play.  
 Western blots would be useful experiments to verify the 
immunocytochemistry results. A western blot for each progesterone receptor type 
at each of the ages analyzed by immunocytochemistry (15.5 dpc – PND 7) would 
provide a reliable secondary method for evaluating progesterone receptor 
expression. Comparison of the western blot results to the staining results and 
agreement between them would confirm the accuracy and dependability of the 
results obtained so far. 
 Completing four immunocytochemistry experiments (as well as four 
western blots) with adult female mouse ovaries for each type of progesterone 
receptor would be helpful in comparing the expression of the receptors in the 
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developing neonate to the expression of the receptors in the fully mature mouse. 
This would be useful in identifying possible trends as the mouse develops into an 
adult. Also, while some data regarding expression in adults may have already 
been published, it is often in reference to pathologies and cancer. It would be 
useful to personally obtain the experimental results with significant findings.  
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Summary of Capstone Project 
 
Not long after fertilization of an egg by sperm, cellular multiplication and 
division quickly begins to assemble and develop the tissues of a new organism in 
a process known as embryogenesis. Even more impressively, it is not long before 
the fetus is already developing its reproductive system for its own reproductive 
purposes in the future. In females, the two ovaries are small organs that contain 
cells called oocytes. Oocytes which have been completely differentiated, or 
matured into a preovulatory stage during menstruation later on in the female’s 
life, may then be released from the female’s ovary and fertilized by sperm to 
create a new organism. This is the essence of fertility. Infertility, therefore, can 
often be the result of an abnormality in the proper development of the oocytes. In 
this case, infertility is characterized as a disorder which is based on disrupted 
oocyte development very early on in embryogenesis, while the new organism is 
still a fetus.  
The development of these reproductive cells known as oocytes is a 
complex process. It is influenced and regulated by many different hormones and 
other signaling molecules, particularly because the new developing organism (in 
the case of most mammals) is still found within its mother. During 
embryogenesis, therefore, the neonate is directly exposed to the mother’s 
hormones and indirectly exposed to compounds in the environment through its 
mother. Examples of these hormones are estrogen, estrogenic compounds and 
mimics, and other steroid hormones. These are molecules which bind receptors on 
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cells in the ovary and/or receptors within cells in the ovary. The binding of these 
hormones and molecules can create an immediate effect in the cell by activating 
signaling cascades where a chain reaction of activation occurs, or they can have 
prolonged effects by activating transcription and expression of genes on the DNA 
within the cell nucleus.  
Estrogen is a hormone which plays an active role in causing these changes 
in the cells throughout the ovaries for most of the female’s lifetime. It has been 
studied extensively and information is available regarding both the effects of the 
hormones as well as the various estrogen receptors which mediate these effects. 
Another steroid hormone involved that plays an equally important role is 
progesterone. Although progesterone’s effects have been studied to some extent, 
its role in the development of the oocytes during embryogenesis is not known and 
it receives little attention in research today.  
The aim of this research was to begin preliminary analysis of 
progesterone’s role in the development of the oocytes using a very basic 
approach. The model organism for this research was the mouse. Male and female 
mice were mated and the gestation (pregnancy) period of the female was 
monitored to keep track of the exact age of the offspring, known as a litter of 
pups. Neonatal mice at ages 13.5 dpc (days post coitum) to PND 7 (post natal 
day) were used for experiments. The ovaries from the female neonatal mice were 
dissected and then an experiment called immunocytochemistry, or staining, was 
performed. The protocol for immunocytochemistry includes a sequence of 
washings to purify impurities from the ovary and preserve it, and also included 
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the addition of primary and secondary antibodies. The specific primary antibody 
would attach to the progesterone receptor of interest, and the secondary antibody 
would attach to the primary antibody and make it fluoresce when the ovaries were 
views on a slide using confocal microscopy. The entire procedure from dissection 
to the completion of immunocytochemistry takes four days.  
After immunocytochemistry was complete and the ovaries were on a slide, 
they were viewed using confocal microscopy. A confocal microscope uses lasers 
to penetrate preserved tissue and allows for the fluorescent secondary antibodies 
inside the tissue to be detected. Pictures were taken of the ovaries and then 
analyzed and compared to see changes in expression of various progesterone 
receptors and to see how the expression of each changes over time.  
Additionally, organ culture experiments were started to manipulate the 
environment that the ovaries were grown in and see what effect these 
progesterone receptors may be mediating in the ovary. Organ culture experiments 
involve dissecting ovaries as had been done previously, but than an incubator is 
used to keep the ovaries alive for a few days and allow for experimental 
manipulation. The environment and temperature of the incubator are similar to 
those that the ovaries would experience if they were within a body. The media, or 
special fluid that the ovaries are grown on within the incubator, also creates a 
nutrient environment for the ovaries as if they were within a living body. This 
media is the variable factor and can be made with the addition of function 
blocking antibodies, which in this case would prevent the progesterone receptors 
from functioning properly. After organ culture, the ovaries were then stained 
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following the same procedure mentioned previously and the ovaries were 
observed using confocal microscopy to see what changes had occurred as a result 
of blocking the progesterone receptors from functioning.  
These were the experiments performed in this project and they allowed for 
identification of four progesterone receptors which are present from 13.5 dpc to 
PND 7 in the neonatal mouse. Our results showed that PGRMC2 is expressed at 
the earliest time point in development, as early as 13.5 dpc. Receptors PR-A and 
PR-B are expressed briefly towards the end of gestation, at around 15.5 – 17.5 
dpc. Generally, however, the three receptor types PR-A and PR-B, PAQR3, and 
PGRMC1 begin expression a few days after birth in the mouse, making an 
appearance at PND 5 or later.  
Two organ culture experiments were performed with a PGRMC2 function 
blocking antibody. PGRMC2 was selected as the target for these experiments due 
to the unique timing of its expression and the unusually strong staining it 
exhibited after immunocytochemistry. PGRMC2 function was inhibited first at 
PND 1 – PND 5. There did not appear to be significant results, or more 
specifically, any changes in oocyte morphology or number. This can be expected 
since the immunocytochemistry experiments showed that PGRMC2 is not 
expressed after PND 1; therefore, it could not mediate any effect on the oocyte. 
PGRMC2 function was then inhibited at 15.5 dpc – PND1. The results of this 
experiment are inconclusive due to possible contamination and small sample size. 
Future experiments to elucidate the mechanisms of progesterone signaling 
in the developing ovary will need to include multiple organ cultures to manipulate 
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each of the four individual receptors mentioned. Additional experiments will need 
to be performed to confirm the findings presented here. For example, a western 
blot experiment could be used to supplement each of the immunocytochemistry 
experiments and would allow for visual quantification of the receptor of interest. 
Agreement between the immunocytochemistry experiments and the western blots 
would be very beneficial in determining the dependability of the results obtained 
to date.  
The future for research on progesterone receptors looks promising. 
Progesterone receptors are receiving more attention due to discoveries of their 
presence in breast and ovarian cancers. Having a timeline of progesterone 
receptors and the time frames within which they appear will be useful in 
determining where developmental errors might have occurred. Also, if future 
research finds that a common industrial compound might serve as an inhibitor (or 
possibly an activator) of a certain progesterone receptor, this research will be 
useful in determining what effects that compound may have on the future fertility 
of neonates who might be indirectly exposed to it during gestation. It would also 
result in regulation of that compound’s use in industry and manufacturing.  
This is just one example of the value of this research. The results which 
have been obtained so far regarding progesterone receptors are interesting, and 
future research will surely indicate that these receptors play an important role 
throughout the entire lifetime of the female. They are involved in proper 
development of the oocytes in a female during embryogenesis, regulating the 
cycles of menstruation decades later throughout the reproductive life span, and 
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also play a role in cancer and tumor growth many more decades later. The 
discoveries yet to be made will be invaluable in more ways than one.  
 
 
 
 
 
 
 
 
 
 
 
 
 
